RDY Dr. Reddys Laboratories ADRs

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. This is an ADR of a company whose stock trades outside of the U.S. as the symbol IS:DRREDDY.

$71.69  -0.05 (-0.07%)
As of 06/22/2021 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  India
Country of incorporation:  India
IPO date:  02/11/2013
Outstanding shares:  166,285,197
Average volume:  104,901
Market cap:   $11,889,391,586
Current dividend yield:  0.47%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    256135203
ISIN:        US2561352038
Sedol:      2748881
Valuation   (See tab for details)
PE ratio:   45.54
PB ratio:   0.07
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy